Robotic Research enhances transportation safety and efficiency through advanced autonomous technology. Their innovations increase security and effectiveness, making travel safer for all.

Arcellx is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration. Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, into the clinic through two programs: ACLX-001 in r/r MM and ACLX-002 in relapsed or refractory acute myeloid leukemia.

GlycoMimetics, Inc., a biopharmaceutical company, engages in the design and development of small molecule therapeutics to mimic the functions of bioactive carbohydrates. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin, and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa. The company was founded in 2003 and is based in Gaithersburg, Maryland.

NexImmune is an early stage biopharmaceutical company developing novel immuno-therapeutics based on the proprietary Artificial IMmune (AIMTM) technology. The AIM technology provides an important advance in the development of immunotherapies for a variety of cancers and other diseases. The AIM technology has been designed to orchestrate specific immune system responses in a highly controllable and reproducible way independent of the healthiness or abundance of the patient’s natural antigen presenting cell (APC) population. Natural APCs are major players in the body’s immune system as they direct the immune system cells in attacks on specifically targeted antigens and cells. However, under certain disease conditions, natural APCs can be damaged, absent or inactive.

Roboteam creates advanced unmanned systems and controllers for defense applications. Their innovative platforms are designed to enhance military operations with cutting-edge technology.

SalubrisBio is a clinical-stage biotechnology company focused on the discovery and development of innovative antibody and protein-based therapeutics, aiming to advance healthcare by addressing unmet medical needs with cutting-edge treatment solutions.

Georgiamune develops innovative immunotherapy treatments for cancer and autoimmune diseases, enabling rapid patient recovery. Their advanced therapies harness the power of the immune system to combat illness effectively.

Cardinality aims to revolutionize Health & Human Services by offering a user-friendly experience comparable to popular products like Apple and Gmail. Their mission is to provide stakeholders with modern, intuitive solutions for everyday tasks in the industry.

RNAimmune specializes in developing mRNA-based therapeutics and vaccines. Their focus is on discovering innovative solutions for various medical conditions using cutting-edge technology.

MiRecule is a biotech startup specializing in developing cutting-edge microRNA-based therapies. They aim to revolutionize medicine by harnessing the power of microRNAs for targeted treatments.

Revolutionizing cell therapy in oncology and beyond with safer, more powerful solutions. Join us in pioneering cutting-edge treatments that push the boundaries of what is possible in the medical field.

Robotic Research enhances transportation safety and efficiency through advanced autonomous technology. Their innovations increase security and effectiveness, making travel safer for all.

Roboteam creates advanced unmanned systems and controllers for defense applications. Their innovative platforms are designed to enhance military operations with cutting-edge technology.

Cardinality aims to revolutionize Health & Human Services by offering a user-friendly experience comparable to popular products like Apple and Gmail. Their mission is to provide stakeholders with modern, intuitive solutions for everyday tasks in the industry.

Arcellx is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration. Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, into the clinic through two programs: ACLX-001 in r/r MM and ACLX-002 in relapsed or refractory acute myeloid leukemia.

GlycoMimetics, Inc., a biopharmaceutical company, engages in the design and development of small molecule therapeutics to mimic the functions of bioactive carbohydrates. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin, and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa. The company was founded in 2003 and is based in Gaithersburg, Maryland.

NexImmune is an early stage biopharmaceutical company developing novel immuno-therapeutics based on the proprietary Artificial IMmune (AIMTM) technology. The AIM technology provides an important advance in the development of immunotherapies for a variety of cancers and other diseases. The AIM technology has been designed to orchestrate specific immune system responses in a highly controllable and reproducible way independent of the healthiness or abundance of the patient’s natural antigen presenting cell (APC) population. Natural APCs are major players in the body’s immune system as they direct the immune system cells in attacks on specifically targeted antigens and cells. However, under certain disease conditions, natural APCs can be damaged, absent or inactive.

Robotic Research enhances transportation safety and efficiency through advanced autonomous technology. Their innovations increase security and effectiveness, making travel safer for all.

Arcellx is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration. Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, into the clinic through two programs: ACLX-001 in r/r MM and ACLX-002 in relapsed or refractory acute myeloid leukemia.

SalubrisBio is a clinical-stage biotechnology company focused on the discovery and development of innovative antibody and protein-based therapeutics, aiming to advance healthcare by addressing unmet medical needs with cutting-edge treatment solutions.

Robotic Research enhances transportation safety and efficiency through advanced autonomous technology. Their innovations increase security and effectiveness, making travel safer for all.

Cardinality aims to revolutionize Health & Human Services by offering a user-friendly experience comparable to popular products like Apple and Gmail. Their mission is to provide stakeholders with modern, intuitive solutions for everyday tasks in the industry.

Arcellx is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration. Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, into the clinic through two programs: ACLX-001 in r/r MM and ACLX-002 in relapsed or refractory acute myeloid leukemia.

GlycoMimetics, Inc., a biopharmaceutical company, engages in the design and development of small molecule therapeutics to mimic the functions of bioactive carbohydrates. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin, and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa. The company was founded in 2003 and is based in Gaithersburg, Maryland.

Robotic Research enhances transportation safety and efficiency through advanced autonomous technology. Their innovations increase security and effectiveness, making travel safer for all.

Arcellx is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration. Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, into the clinic through two programs: ACLX-001 in r/r MM and ACLX-002 in relapsed or refractory acute myeloid leukemia.

Inviter helps you to send video invitations, video greetings to your friends, family, users, subscribers, followers, employees and customers. Video moves people and inviter’s video messaging helps you to connect to your audience group and makes them feel your message. We use video to create a sense of community. Whether you are planning a personal event or business event, invite your guests in a unique & create way. Other additional features we offer are RSVP reports, Email Reports, Customization, 24X7 dedicated support and reasonable pricing plans. Either it is a birthday of your customer or a gentle reminder for an appointment, video message does its job. Such idea is where “Inviter” comes in, bringing a lime light to communication using video messaging services. Our services are unique, cost-effective and makes your business a loyal and personalized community.